Clinical Trial VICCHEM1146


Ofatumumab in combination with high dose cytarabine chemoimmunotherapy for patients with newly diagnosed Mantle Cell Lymphoma

Principal Investigator(s)

Nishitha Reddy


  • Protocol No. VICCHEM1146
  • Open Date: 08/14/2012
  • Staging: Phase II
  • Age Group: Adults
  • Scope: National
  • Objective: To determine the overall response rate (ORR), and in particular, the complete remission rate (CRR) in previously untreated MCL treated with ofatumumab in combination with aggressive chemo-immunotherapy
  • Disease Sites: Lymphoma
  • Therapies: Chemotherapy - cytotoxic; Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: Cyclophosphamide (CTX); Cytarabine (ARA-C); Dexamethasone; Doxorubicin; G-CSF; Leucovorin (Folinic acid); Mesna; Methotrexate; Ofatumumab; Vincristine
  • Participating Institutions: Vanderbilt University
  • National Clinical Trial ID: NCT01527149
  • Secondary Protocol No: Not Specified



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.